PHARNEXT: Shareholder Letter: Time to reveal Pharnext true value

PARIS, France, January 11th, 2023, 8:30 am CET - Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for rare

Related Keywords

Phoenix ,Arizona ,United States ,Paris ,France General ,France ,Canada ,Israel ,Schwann ,Baden Wüberg ,Germany ,Fabreguettes Leib ,Hugo Brugi ,Sukaina Virji ,Xavier Paoli ,James Kuo ,Joshua Schafer ,Mary Jane Elliott ,Rob Quinn ,Alexandra Harrison ,Company On ,Edison Investment Research ,Financial Press Relation ,Euronext Growth Stock Exchange ,Media Relations International ,Consilium Strategic Communications ,Chief Executive Officer ,Overall Neuropathy Limitation Scale ,Open Label Extension ,Managing Director ,Healthcare Ventures ,Charcot Marie Tooth Disease Type ,Overall Neuropathy Limitations Scale ,Meter Walk Test ,Quantified Muscular Testing ,Patient Global Impression ,Charcot Marie Tooth Neuropathy Score ,Charcot Marie Tooth Disease ,Shows Sustained Benefit ,Announces On Schedule Completion ,Patient Enrollment ,Pivotal Phase ,Announces First Patient Enrolled ,Pharnext ,Shareholder ,Setter ,Dime ,Reveal ,True ,Value ,